Patent Law Weblog
recent posts
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
- Meanwhile, Back at the PTAB with CRISPR – Update
about
Month: April 2016
-
Strafford will be offering a webinar/teleconference entitled "Navigating the New EU Unitary Patent System and Unified Patent Court — Strategic Considerations for U.S. Applicants and Patentees" on April 21, 2016 from 1:00 to 2:30 pm (EDT). Dr. Hazel Ford of Finnegan Henderson Farabow Garrett & Dunner and Leythem A. Wall of Finnegan Europe will provide…
-
The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Evidence at the PTAB: New AIA Rules" on April14, 2016 from 2:00 to 3:00 pm (ET). Judge Michael Tierney of the U.S. Patent and Trademark Office; Lissi Mojica of Dentons; and Jon Wright of Sterne, Kessler, Goldstein & Fox will discuss the rule…
-
Technology Transfer Tactics will be offering a webinar entitled "Preparing for Patent Litigation: Practical Strategies for University Tech Transfer Offices" on April 21, 2016 from 1:00 to 2:00 pm (Eastern). Alfonso Garcia Chan of Shore Chan DePumpo, LLP; Michael Pratt, Interim Director of Technology Development, Boston University; Teri Schultz, Director, Office of Technology Management, University…
-
By Anthony D. Sabatelli* — In an interesting case decided last month, the Federal Circuit ruled that it cannot address whether the U.S. Patent and Trademark Office's 2014 Interim Guidance on Patent Subject Matter Eligibility exceeds the scope of the Supreme Court's decisions in this area. This case was an appeal from a final decision…
-
By Kevin E. Noonan — The Biologic Price Control and Innovation Act (BPCIA), enacted as part of President Obama's Affordable Care Act (better known as "Obamacare," Public Law 111-148), provided for the first time in the U.S. a path for FDA approval of biosimilar drugs, i.e., "generic" versions of biologic drugs that, unlike generic versions…
-
By Andrew Williams — Earlier today, the U.S. Food and Drug Administration approved Celltrion's application to market Inflectra, a biosimilar to Janssen Biotech Inc.'s REMICADE (infliximab) anti-TNF-α antibody. This marks only the second biosimilar approved by the FDA pursuant to the BPCIA, and only the first to approve a therapeutic monoclonal antibody. Biologics License Application…
-
U.S. Patent to Consumer Marketing, Based on Avatar Choices, Survives § 101 Challenge By Joseph Herndon — On March 22, 2016, the U.S. District Court for the District of Delaware issued a Memorandum Opinion in a case captioned Treehouse Avatar LLC v. Valve Corp., in which software patent claims survived a patent eligibility challenge. Treehouse…
-
By Coalition for 21st Century Medicine* — The collective experience of the Members of the Coalition for 21st Century Medicine in trying to obtain much needed patent protection for their novel, life-saving technologies has led to one inescapable conclusion: It is critical to the future of precision medicine that the Supreme Court review the Federal…
-
April 5, 2016 – "Two Views of the U.S. Patent and Trademark Office" (John Marshall Law School Center for Intellectual Property, Information & Privacy Law) – Chicago, IL April 5, 2016 – "Patents After the AIA: Evolving Law and Practice – Part 1" (American Intellectual Property Law Association) – 12:30 to 2:00 pm (Eastern) April…
-
The American Intellectual Property Law Association (AIPLA) will be offering a three-part webinar series that will further expand upon the forthcoming publication "Patents After the AIA: Evolving Law and Practice" on April 5, April 20, and May 11, 2016. In part 1 of the series, to be held from 12:30 to 2:00 pm (Eastern) on…
Patent Docs 